SpringerLink

Incluye referencias bibliográficas

Preface; Acknowledgments; Contents; List of Contributors; 1: Radiological Imaging in Urological Cancers; 1.1 Introduction; 1.2 Renal Cancer; 1.2.1 General Information; 1.2.2 Imaging Techniques; 1.2.2.1 Ultrasonography; 1.2.2.2 Computed Tomography; 1.2.2.3 Magnetic Resonance Imaging; Malignant Tumors of Renal Pelvis; Metastases; Lymphoma; Primary Renal Mesenchymal Tumors; 1.2.3 Staging of Renal Tumors; 1.2.4 Intervention in Renal Masses; 1.3 Bladder Cancer; 1.3.1 General Information; 1.3.2 Imaging Features; 1.3.2.1 Ultrasonography; 1.3.2.2 Computed Tomography.

1.3.2.3 Magnetic Resonance Imaging1.3.3 Staging; 1.3.3.1 Lymph Node Metastasis; 1.3.3.2 Metastasis Staging; 1.3.4 Monitoring After Treatment; 1.4 Prostate Cancer; 1.4.1 General Information; 1.4.2 Imaging Features; 1.4.2.1 Ultrasonography; 1.4.2.2 Computed Tomography; 1.4.2.3 Magnetic Resonance Imaging; 1.4.3 Local Staging of Patients with Biopsy-Proven Prostate Cancer; 1.4.3.1 Lymph Node Metastasis; 1.4.3.2 Distant Metastasis; 1.4.3.3 Preprocedural Assessment; 1.4.3.4 Metabolic Imaging; 1.4.3.5 Evaluation of Recurrence; References.

2.10 Surgical Management of Muscle-Invasive Bladder CancerReferences; 3: Target Volume Delineation Guidelines in Bladder Cancer; 3.1 Anatomy; 3.2 Role of Radiotherapy for Locoregional Disease; 3.3 Target Volume Delineation; 3.4 Definitive Radiotherapy for the Intact Bladder; 3.4.1 Gross Tumor Volume; 3.4.2 Clinical Target Volume; 3.4.3 Role of Elective Nodal Irradiation; 3.4.4 Planning Target Volume; 3.5 Adjuvant Setting; References; 4: Bladder Preservation Therapies in Bladder Cancer; 4.1 Introduction; 4.2 Management of Non-muscle-Invasive Bladder Cancer.

2: Management of Non-muscle-Invasive and Muscle-Invasive Bladder Cancers2.1 Introduction; 2.2 Management of Non-muscle-Invasive Bladder Cancer; 2.3 Repeat/Restaging Transurethral Resection; 2.4 Intravesical Chemotherapy; 2.5 Intravesical Immunotherapy; 2.6 Treatment Alternatives During the Global Shortage of BCG; 2.6.1 Alternative BCG Schedules; 2.6.2 Alternative Intravesical Chemotherapy Applications; 2.7 Future Perspectives; 2.8 Treatment of Disease Unresponsive to or Relapsing After BCG Vaccination; 2.9 Upfront Cystectomy for Very High-Risk NMIBC.

4.3 Treatment of Muscle-Invasive Disease4.3.1 Monotherapy; 4.3.2 Multimodal Approach; 4.4 Metastatic Disease and Recurrences; 4.5 Irradiation Techniques; 4.5.1 Simulation, Target Volume, and Fields; 4.5.2 Tumor Localization; 4.5.3 Target Delineation; 4.5.4 Doses and RT Schedules; 4.5.5 IMRT and IGRT; 4.5.6 Brachytherapy; References; 5: Systemic Therapy for Bladder Cancer; 5.1 Introduction; 5.2 Systemic Therapies in Muscle-Invasive Bladder Cancer; 5.3 Treatment of Advanced and Metastatic Disease; 5.3.1 DNA-Targeted Chemotherapy; 5.3.2 Targeted Therapies; 5.3.3 Immunotherapy.

This evidence-based, state of the art guide to the management of urological malignancies, including bladder cancer, prostate cancer, and testicular cancer, is designed to serve as an easy-to-consult reference that will assist in daily decision making and the delivery of optimal care for individual patients within a multidisciplinary setting. Readers will find up-to-date information on patient selection and the full range of treatment modalities, including modern radiotherapy techniques, systemic chemotherapy, surgical procedures (including robotic surgery and other minimally invasive approaches), hormonal therapies, immunotherapy, and focal therapies. With regard to radiotherapy, the coverage encompasses everything from delineation of tumor volumes and organs at risk based on CT simulation through to delivery of stereotactic body radiotherapy, intensity-modulated radiation therapy, tomotherapy, volumetric modulated arc therapy, and proton therapy. The authors are leading authorities with international reputations who have been selected for their expertise in the topic that they address. The book will be of value for all practicing urooncologists as well as other oncology fellows and residents interested in urooncology.